학술논문
Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
Document Type
article
Author
Maria Isabel Lopes; Leticia P Bonjorno; Marcela C Giannini; Natalia B Amaral; Pamella Indira Menezes; Saulo Musse Dib; Samara Libich Gigante; Maira N Benatti; Uebe C Rezek; Laerte L Emrich-Filho; Betania A A Sousa; Sergio C L Almeida; Rodrigo Luppino Assad; Flavio P Veras; Ayda Schneider; Tamara S Rodrigues; Luiz O S Leiria; Larissa D Cunha; Jose C Alves-Filho; Thiago M Cunha; Eurico Arruda; Carlos H Miranda; Antonio Pazin-Filho; Maria Auxiliadora-Martins; Marcos C Borges; Benedito A L Fonseca; Valdes R Bollela; Cristina M Del-Ben; Fernando Q Cunha; Dario S Zamboni; Rodrigo C Santana; Fernando C Vilar; Paulo Louzada-Junior; Rene D R Oliveira
Source
RMD Open, Vol 7, Iss 1 (2021)
Subject
Language
English
ISSN
2056-5933
Abstract
Objective To evaluate whether the addition of colchicine to standard treatment for COVID-19 results in better outcomes.Design We present the results of a randomised, double-blinded, placebo-controlled clinical trial of colchicine for the treatment of moderate to severe COVID-19, with 75 patients allocated 1:1 from 11 April to 30 August 2020. Colchicine regimen was 0.5 mg thrice daily for 5 days, then 0.5 mg twice daily for 5 days. The primary endpoints were the need for supplemental oxygen, time of hospitalisation, need for admission and length of stay in intensive care unit and death rate.Results Seventy-two patients (36 for placebo and 36 for colchicine) completed the study. Median (and IQR) time of need for supplemental oxygen was 4.0 (2.0–6.0) days for the colchicine group and 6.5 (4.0–9.0) days for the placebo group (p